A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)ROCKET–VOYAGER

• Age ≥ 18 years to 54 years with a diagnosis of AD according to the American Academy of Dermatology (AAD) Consensus Criteria (2014) present for at least 12 months • History of inadequate response to topical corticosteroids (TCS) of medium, high, or higher potency (with or without topical calcineurin inhibitors) • Subjects with previous systemic treatment for AD are also considered as inadequate responders to topical treatments and are potentially eligible to be included in the study after appropriate washout. • Validated Investigator’s Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3

• Treatment with a biologic product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1 • Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1: o Systemic corticosteroids o Systemic immunosuppressants o Phototherapy o Janus kinase inhibitors • Treatment with any of the following medications or therapies within 1 week, prior to Day 1: o TCS of any potency o Topical calcineurin inhibitors (TCI) o Topical Phosphodiesterase-4 inhibitors (PDE4) o Other topical immunosuppressive agents o Combination topical agents containing a corticosteroid or calcineurin inhibiting component, PDE4 inhibitors, or other topical immunosuppressive agents • Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 pre-randomization. • Treatment with any meningococcal vaccine within 1 year prior to screening, or treatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5 years prior to screening